Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Medipal/JCR to Pair Up for Mucopolysaccharidosis Type IIIB Drug
Medipal Holdings and JCR Pharmaceuticals said on September 28 that they will be joining forces to develop and commercialize JR-446 for the indication of mucopolysaccharidosis type IIIB (MPS IIIB), a lysosome disease also known as Sanfilippo syndrome type B. The…
To read the full story
Related Article
- Medipal, JCR Expand Tie-Up to GM2 Gangliosidosis Drug JR-479
September 1, 2025
- Medipal, JCR Kick Off Japan PI/II of MPS IIIB Therapy
December 4, 2024
- Medipal/JCR’s MPS IIIB Drug Now in Line to Enter Clinic
July 2, 2024
BUSINESS
- Kowa Wins Hong Kong Approval for Livalo, Glanatec OK in Vietnam
July 3, 2026
- Medinet Exercises Option for Stempeucel Rights in Japan
July 3, 2026
- Average Pay at 21 Japan Drug Makers Up 3.8%, Chugai Tops 13 Million Yen
July 2, 2026
- Mochida Seeks Pediatric Expansion for Urece
July 2, 2026
- Kowa Files US NDA for Nicox’s Glaucoma Drug
July 2, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…